LIQUID MANUFACTURING LIKE SYRUPS & SUSPENSION (PHARMA UNIT) [3630]
The foundation of the modern Indian pharmaceutical Industry was laid at the start of the current century when in 1901, a small factory known as the Bengal Chemical & Pharmaceutical works was established in Kolkata. Though the two world Wars gave a Phillip to the development of industry, the progress made under British rule was not significant except the British introduced into this country the allopathic system of medicine. The country depended largely for its requirements on U.K., France and Germany. The development of Indian Drugs and pharmaceuticals Industry was not commensurate with the size of this country and the growing needs of people, when Indian embarked on its planned economic expansion industry has been substantial and many sides with the result that it has becomes one of the leading industries. India is now producing a larger quantity of varied pharmaceuticals products. In 1948, the sale of pharmaceuticals products. In 1948, the sale of pharmaceutical products amounted to just Rs. 100 million. By 1954 the figure had rised to Rs. 540 million and by 1960 to Rs. 700 million. The figure stood at between Rs. 1500 million in 1965 and Rs. 4000 millions in 1975, Rs. 12000 millions in 1980 and above Rs. 18,500 millions presently. The restrictions, however, continued on import of non essential patent and proprietory medicen for which suitable substitutes manufactured indigenously were available. Prior to the launching of the second plan the manufacture of pharmaceuticals was limited largely to the processing of bulk imported drugs into tablets, capsules and other formulations. Indian firms under agreement with foreign firms are making injectables, powders ointments and liquids, and were also filling antibiotics. Certain units were producing biological extracts, vacines, and syrup. Alkalods, like quinins stry-chinea, caffeine, and morphine were also being extracted. It was however obvious that the country could not forever be dependent on foreign manufacturers for both finished drugs and basis raw materials. With the changing political climate, pharmaceutical manufacturers in India were encouraged to take up the manufacture of basis drugs wherever it was economically possible and technically feasible. A system of collaboration was instituted, under which Indian manufacturers in association with established firms in U.S.A., Italy, U.K. began to produce a fairly comprehensive range of basic items. While the allocation of foreign exchange for the import of raw materials and basic intermediates for the production of drugs, has been more or less static the value of products manufactured has increased progressively several fold clearly indicating the growing stature, of industry and its capacity to switching over to basic raw materials and components of indigenous origin, and now the country is stated to achieve self, sufficiency in synthetic drugs of the sulpha group, anti T.B. drugs, Vitamins, and intermediates. It has, however, been found that the present installed capacity is insufficient to meet the over growing demand of the massive population and the scope for new units to come up is substantial.
COST ESTIMATION
Plant Capacity 150000 Bottles/Day
Land & Building (2200 sq.mt) Rs. 1.76 Cr
Plant & Machinery Rs. 90 Lac
Working Capital for 2 Months Rs. 4.16 Cr
Total Capital Investment Rs. 6.98 Cr
Rate of Return 55%
Break Even Point 33%
INTRODUCTION
OVERVIEW OF INDIAN PHARMACEUTICALS INDUSTRY
EXHIBIT 1 MULTIPLE DIGITAL AND ADVANCED ANALYTICS
APPLICATIONS IN PHARMA VALUE CHAIN
INDIA MARKET DYNAMICS & IMPLICATIONS FOR INDIA PHARMA
EXHIBIT 2 INCREMENTAL GROWTH IN THE INDIAN
PHARMACEUTICAL MARKET
OPPORTUNITIES FOR INDIA AS A GLOBAL SUPPLY DESTINATION
INSTITUTIONALIZING QUALITY AND COMPLIANCE EXCELLENCE
EXHIBIT 3 OUTSTANDING QUALITY INVOLVES BUILDING QUALITY IN THE ORGANIZATION’S OPERATING SYSTEMS, MANAGEMENT SYSTEMS
AND PEOPLE SYSTEMS
BUILDING OPERATIONAL EXCELLENCE
ALTERNATE SOURCING AND SELF-SUFFICIENCY IN APIS/INTERMEDIATES
MARKET POSITION OF PHARMACEUTICALS INDUSTRY
A USD 55 BILLION MARKET BY 2020 WITH POTENTIAL FOR MORE
MASS THERAPIES WILL REMAIN IMPORTANT EVEN THOUGH
SPECIALTY THERAPIES WILL INCREASE SHARE
INCREASING INVESTMENTS IN THE SECTOR
PRESENT MANUFACTURERS/SUPPLIERS
FORMULATION OF COUGH SYRUP
FORMULATION OF COUGH SYRUP (HERBAL)
FORMULATION OF PARACETAMOL SYRUP
FORMULATION OF PARACETEMOL SYRUP
FORMULATION OF PHARMACEUTICAL SOLUTION FORM OF PARACETAMOL IN THE PEDIATRIC USE
FORMULATION 1
FORMULATION 2
FORMULATION 3
FORMULATION 4
FORMULATION 5
FORMULATION 6
FORMULATION OF POLY HERBAL SYRUP (ANTI DIABETIC)
STEPS IN MANUFACTURING PROCESS
PREPARATION OF ACTIVE SOLUTION
PREPARATION OF FLAVOR SOLUTION
PREPARATION OF VEHICLE SOLUTION
PREPARATION OF FINAL SYRUP
COMPOSITION OF ANTICID SUSPENSION
PROCESS FLOW DIAGRAM OF PHARMACEUTICAL SYRUP
LIQUID MIXING & BLENDING
BLENDING FOR CONSISTENCY
METHODS OF PREPARATION OF SYRUPS
1. SOLUTION WITH THE AID OF HEAT
2. SOLUTION BY AGITATION WITHOUT THE AID OF HEAT
3. ADDITION OF SUCROSE TO A MEDICATED LIQUID OR TO
A FLAVORED LIQUID
4. PERCOLATION
PRESERVATION OF SYRUP
PRODUCTION OF COUGH MIXTURES AND PHARMACEUTICAL SYRUPS
STAGE 1
STAGE 2
STAGE 3
OTHERS FORMULATIONS OF SYRUPS
SYRUPS
ANTI ALLERGIC COUGH SYRUP
EDIATRIC SYRUP OF PARACETAMOL
VICKS FORMULA 44 COUGH MIXTURE
PARACETAMOL - VITAMINIC SYRUP
MULTIVITIMAN SYRUP
COUGH SYRUP
LIQUIDS
1. GENERAL TONIC (MULTI VITAMIN)
2. SODIUM GLYCEROPHOSPHATE
3. VITAMIN B COMPLEX WITH DIGESTIVE ENZYMES
TONIC LIQUID
DETAILED MANUFACTURING PROCESS OF SYRUP (LIQUID)
FILTERATION
BOTTLING
FLOW DIAGRAM OF MIXING PLANT
SUPPLIERS OF RAW MATERIALS
SUPPLIERS OF PLANT AND MACHINERY
DISTILLED WATER PLANT
STORAGE VESSEL (STORAGE TANKS)
INSTRUMENTATION & PROCESS CONTROL EQUIPMENTS
LABORATORY EQUIPMENTS
APPENDIX – A:
01. PLANT ECONOMICS
02. LAND & BUILDING
03. PLANT AND MACHINERY
04. OTHER FIXED ASSESTS
05. FIXED CAPITAL
06. RAW MATERIAL
07. SALARY AND WAGES
08. UTILITIES AND OVERHEADS
09. TOTAL WORKING CAPITAL
10. TOTAL CAPITAL INVESTMENT
11. COST OF PRODUCTION
12. TURN OVER/ANNUM
13. BREAK EVEN POINT
14. RESOURCES FOR FINANCE
15. INSTALMENT PAYABLE IN 5 YEARS
16. DEPRECIATION CHART FOR 5 YEARS
17. PROFIT ANALYSIS FOR 5 YEARS
18. PROJECTED BALANCE SHEET FOR (5 YEARS)
